ALX Oncology Holdings Inc. (NASDAQ:ALXO – Get Free Report) insider Sophia Randolph sold 12,000 shares of the business’s stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $15.94, for a total transaction of $191,280.00. Following the transaction, the insider now owns 330,349 shares of the […]
ALX Oncology Holdings Inc. (NASDAQ:ALXO – Get Free Report) insider Sophia Randolph sold 12,000 shares of ALX Oncology stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $15.94, for a total transaction of $191,280.00. Following the completion of the transaction, the insider now owns 330,349 […]
ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma ("R/R B-NHL") tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
– Twenty patients with indolent and aggressive R/R B-NHL received evorpacept plus standard rituximab and lenalidomide – Evorpacept plus R2 was well tolerated with a safety profile similar to.
– Twenty patients with indolent (n=18) and aggressive (n=2) R/R B-NHL received evorpacept plus standard rituximab and lenalidomide (“R2”)– Evorpacept plus.